Assets by Subsidiary of DOD Biotech Public Company Limited for the Purchase and Acceptance of Transfer of the Entire Business of BGP Spectrum Power Co., Ltd., and Establishment of Subsidiary, Classified as
Assets by Subsidiary of DOD Biotech Public Company Limited for the Purchase and Acceptance of Transfer of the Entire Business of BGP Spectrum Power Co., Ltd., and Establishment of Subsidiary, Classified as
. As a result, EBITDA in 1H21 increased by 1.1%YoY despite soften core service revenue, offset by cost control in SG&A. With the 700MHz spectrum license and 26GHz spectrum license acquired in 1H21, D&A
Bt6,311mn, -5.0% YoY and -8.1% QoQ. Excluding unrealized FX loss, normalized NPAT was 6,345mn, -7.0% YoY due to higher spectrum amortization and -5.8% QoQ from lower core service revenue. The full- year
was Bt6,644mn, decreasing -1.7%YoY as D&A rose from new spectrum and expansion and decreasing -7.3%QoQ from unrealized foreign exchange loss and tax benefit in 4Q20. Market and Competitive Environment
, and minimum payment on TOT’s 2100MHz spectrum. In this MDA material, we present a financial income statement based on pre-TFRS for comparison with FY19. 2. In 4Q20, according to the Royal Decree No. 695
) was Bt7,004mn -7.5% YoY and -0.9% QoQ. 2020 Outlook In February, AIS won the bid of spectrum band for 5G development to secure long term leadership and to build new revenue stream in the future as well
) was Bt7,004mn -7.5% YoY and -0.9% QoQ. 2020 Outlook In February, AIS won the bid of spectrum band for 5G development to secure long term leadership and to build new revenue stream in the future as well
despite flat service revenue, compensate by well-cost control. D&A increased by 2.7% YoY from spectrum license of 700MHz and 2.6GHz acquired in 9M21. Reported net profit was Bt20,059mn, decreasing -1% YoY
serving new content to our customers. D&A costs showed a minor increase (0.8% YoY) mainly from the increase of amortization of the spectrum license and depreciation from 5G network rollout, partially offset